Patient characteristics
| Characteristic . | Result . |
|---|---|
| Baseline characteristics, N = 154 patients | |
| Age, y | |
| Median (range) | 42 (17-56) |
| 45 y or more | 66 |
| Sex ratio, M/F | 89/65 |
| CNS involvement | 7 |
| Anthracycline, IDA/DNR* | 83/71 |
| Leukocyte count | |
| Median (range) | 17 × 109/L (0.5 × 109/L to 626 × 109/L) |
| 25 × 109/L or more | 66 |
| Immunophenotyping | |
| B-lineage ALL | 154 |
| Myeloid markers† | 10 (of 150) |
| Cytogenetics, N = 141 patients | |
| Hyperploidy | 12 |
| Monosomy 7 | 13 |
| NN-AN/AA | 102/39 |
| NN/AN-AA | 15/126 |
| Ph+ | 122 |
| Additional abnormalities | 91 |
| Ph duplication | 20 |
| RT-PCR, N = 142 patients | |
| m-bcr | 97 |
| M-bcr | 40 |
| m/M-bcr | 5 |
| Characteristic . | Result . |
|---|---|
| Baseline characteristics, N = 154 patients | |
| Age, y | |
| Median (range) | 42 (17-56) |
| 45 y or more | 66 |
| Sex ratio, M/F | 89/65 |
| CNS involvement | 7 |
| Anthracycline, IDA/DNR* | 83/71 |
| Leukocyte count | |
| Median (range) | 17 × 109/L (0.5 × 109/L to 626 × 109/L) |
| 25 × 109/L or more | 66 |
| Immunophenotyping | |
| B-lineage ALL | 154 |
| Myeloid markers† | 10 (of 150) |
| Cytogenetics, N = 141 patients | |
| Hyperploidy | 12 |
| Monosomy 7 | 13 |
| NN-AN/AA | 102/39 |
| NN/AN-AA | 15/126 |
| Ph+ | 122 |
| Additional abnormalities | 91 |
| Ph duplication | 20 |
| RT-PCR, N = 142 patients | |
| m-bcr | 97 |
| M-bcr | 40 |
| m/M-bcr | 5 |
CNS indicates central nervous system; IDA, idarubicin; DNR, daunorubicin; Ph, Philadelphia chromosome; m-bcr, minor breakpoint cluster region; and M-bcr, major breakpoint cluster region.
Anthracycline randomly allocated for the induction course.
Defined as the coexpression of CD34, CD33, and CD13 antigens (available in 150 patients).